In additional clinical trials, researchers are evaluating IFN-β expressing MSCs in ovarian cancer (NCT02530047) at MD Anderson Cancer Center, and the safety and anti-tumor capacity of TRAIL-modified MSCs in metastatic non-small cell lung cancer (NCT03298763) at University College London Hospital. This evidence concerns the gene IFNB1 and neoplasm.